Universe Pharmaceuticals (UPC)
Nasdaq Market Closed
Universe Pharmaceuticals Inc. is a pharmaceutical and healthcare products company focused primarily on traditional Chinese medicine, or TCM, derivative products. The company develops, manufactures, markets, sells, and distributes products that are aimed largely at older consumers, with an emphasis on common health needs associated with ageing and general physical well-being.
Its product portfolio is grouped mainly into two areas. One category covers treatments and relief products for chronic health conditions often seen among elderly patients, with formulations positioned around wellness, longevity, and management of recurring symptoms. The second category includes cold and flu medications, a more seasonal and broadly used product segment. In addition to its own TCM-based products, Universe Pharmaceuticals sells items produced by third-party manufacturers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.
The company operates in a market where traditional medicine remains an established part of healthcare consumption, particularly in China and among consumers familiar with TCM practices. Its commercial approach combines manufacturing capabilities with distribution and sales of complementary healthcare products, giving it exposure to both proprietary and third-party product lines.
Universe Pharmaceuticals is distinctive as a listed small-cap healthcare company centered on TCM derivatives rather than conventional branded pharmaceuticals alone. Its business depends on product acceptance, regulatory compliance, manufacturing quality, distribution reach, and demand from ageing populations seeking treatments for chronic conditions and everyday illnesses. The company’s focus on elderly consumers places it within a healthcare niche shaped by demographics, consumer trust, and the continued use of traditional formulations alongside modern medical products.
Last updated
- Market Cap
- $2,047,168
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- —
- Sector
- —
- Industry
- —
- Address
- —
No recent news is linked to this listing.
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $2,047,168
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- —
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- —
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- —
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- —
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- —
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- —
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- —
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- —
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- —
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- —
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- —
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- —
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- —
Income Statement
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Revenue | 17.86B | 23.02B | 32.31B | 40.14M | 47.98M |
| Cost of revenue | 11.56B | 16.95B | 21.99B | 18.25M | 22.66M |
| Gross profit | 6.3B | 6.07B | 10.32B | 21.89M | 25.33M |
| Operating income | -2.92B | -8.02B | -3.97B | -7.02M | 13.51M |
| EBITDA | -2.4B | -7.53B | -3.46B | -6.48M | 13.96M |
| Net income | -3.67B | -8.73B | -6.58B | -7.91M | 11.32M |
| Income taxes | — | 606.7M | 2.25B | 815.32K | 2.36M |
| Interest expense | -232.04M | -278.17M | -156.79M | -162.4K | -101.6K |
| Other operating expenses | 0 | 0 | 0 | 0 | 80.43K |
| Total operating expenses | 9.22B | 14.09B | 14.28B | 28.91M | 11.82M |
| Basic EPS | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 2,148 |
| Diluted EPS | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 2,148 |
Balance Sheet
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Total assets | 69.3B | 67.95B | 41.72M | 59.54M | 70.14M |
| Total liabilities | 13.17B | 22.45B | 13.75M | 13.1M | 11.21M |
| Total equity | 56.13B | 45.5B | 27.97M | 46.44M | 58.93M |
| Cash & equivalents | 33.59B | 29.5B | 5.29M | 5.71M | 8.08M |
| Current assets | 53.6B | 51.64B | 25.27M | 41.51M | 50.48M |
| Current liabilities | 13.17B | 20.31B | 13.75M | 13.1M | 11.21M |
| Accounts payable | 1.67B | 4.91B | 4.59M | 3.08M | 5.31M |
| Receivables | 15.29B | 18.57B | 12.94M | 15.18M | 15.57M |
| Inventories | 4.68B | 2.72B | 3.52M | 2.22M | 5.2M |
| Long-term debt | — | 2.14B | — | — | — |
Cash Flow
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Operating cash flow | -5.05B | -9.51B | 1.12B | -1.3M | -2.06M |
| Investing cash flow | -341.81M | -361.29M | -44.17M | -3.91M | -13.97M |
| Financing cash flow | 9.73B | 33.95B | -1.39B | 3.32M | 13.5M |
| Change in cash | 4.09B | 24.21B | -426.21M | -2.37M | -1.98M |
| Net income | -3.67B | -8.73B | -6.58B | -7.91M | 11.32M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SCHEDULE 13D — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 4 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| form 4 | Form 4 — Lai Gang | View Filing | |
| form 4 | Form 4 — Lai Gang | View Filing | |
| form 4 | Form 4 — Lai Gang | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 3 — Universe Pharmaceuticals INC | View Filing | |
| form 3 | Form 3 — Lai Gang | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SCHEDULE 13G/A — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SCHEDULE 13G/A — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SCHEDULE 13G — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | NT 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SCHEDULE 13G — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 424B5 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 424B4 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | EFFECT — Universe Pharmaceuticals INC | View Filing | |
| edgar index | CORRESP — Universe Pharmaceuticals INC | View Filing | |
| edgar index | F-1/A — Universe Pharmaceuticals INC | View Filing | |
| edgar index | CORRESP — Universe Pharmaceuticals INC | View Filing | |
| edgar index | UPLOAD — Universe Pharmaceuticals INC | View Filing | |
| edgar index | F-1 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SC 13G/A — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | NT 20-F — Universe Pharmaceuticals INC | View Filing | |
| edgar index | EFFECT — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | F-3 — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 6-K — Universe Pharmaceuticals INC | View Filing | |
| edgar index | SC 13G — Universe Pharmaceuticals INC | View Filing | |
| edgar index | 20-F — Universe Pharmaceuticals INC | View Filing |